Abstract: Objective: To investigate the effects of slow intravenous infusion of low-dose mannitol on cardiac troponin T （cTnT）, Creactive
protein （CRP）, tumor necrosis factor-α （TNF-α）, and interleukin-6 （IL-6） levels after cardiopulmonary bypass （CPB）
cardiac surgery, and to evaluate the efficacy of this therapeutic strategy in mitigating postoperative adverse reactions. Methods: A total
of 71 patients who underwent CPB cardiac surgery at the Third Affiliated Hospital of Xinxiang Medical University from June 2020 to
March 2022 were included in the study. Patients were randomly divided into a control group and an experimental group. The control
group received conventional treatment, while the experimental group received additional low-dose mannitol infusion therapy based on
conventional treatment. The levels of cTnT, CRP, TNF-α, and IL-6 were compared at different time points postoperatively between the
two groups. Results: The levels of cTnT, CRP, TNF-α, and IL-6 increased initially and then decreased in both groups postoperatively,
with peak levels observed at 36 hours, 2 days, 6 hours, and 12 hours postoperatively, respectively. There were statistically significant
differences in intergroup comparisons, time effects, and trends of change（ P<0.05）. The peak levels of these indicators were lower, and
the decrease rate was faster in the experimental group. Conclusion: Slow intravenous infusion of low-dose mannitol can effectively
reduce the levels of cTnT, CRP, TNF-α, and IL-6 after CPB cardiac surgery, alleviate postoperative adverse reactions, and holds
clinical promotional value.

Key words: cardiopulmonary bypass, cardiac surgery, low-dose mannitol, cardiac protection, inflammatory markers, myocardial injury